CSTONE PHARMA-B (02616) announced that the global multicenter Phase II clinical trial of its core pipeline product CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has completed the first patient enrollment in Australia. The trial is currently actively enrolling patients in Australia and China, with plans to expand to the United States in the future.

CS2009 is a novel trispecific antibody independently developed by CSTONE PHARMA-B from molecular design, targeting PD-1, VEGFA, and CTLA-4. Through synergistic mechanisms, it achieves multi-dimensional anti-tumor effects and demonstrates first-in-class/best-in-class potential.

CS2009 features a differentiated molecular design that combines three clinically validated targets. It can reactivate nearly exhausted tumor-infiltrating T cells and possesses VEGF neutralization capabilities comparable to existing anti-VEGF antibodies. The drug has broad disease coverage, including but not limited to non-small cell lung cancer, small cell lung cancer, liver cancer, gastric cancer, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and esophageal cancer.